Nurix Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire MAY 16, 2025 4:00 PM EDT
   SAN FRANCISCO, May 16, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinic...
   READ ARTICLE

2. Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

   GlobeNewswire MAY 15, 2025 7:00 AM EDT
   SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinic...
   READ ARTICLE

3. Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

   GlobeNewswire MAY 14, 2025 9:30 AM EDT
   SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinic...
   READ ARTICLE

4. Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

   GlobeNewswire APR 28, 2025 4:00 PM EDT
   Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Comp...
   READ ARTICLE

5. Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

   GlobeNewswire APR 25, 2025 1:00 PM EDT
   Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molec...
   READ ARTICLE

6. Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

   GlobeNewswire APR 17, 2025 7:00 AM EDT
   Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multip...
   READ ARTICLE

7. Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire APR 11, 2025 4:01 PM EDT
   SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clin...
   READ ARTICLE

8. Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

   GlobeNewswire APR 8, 2025 4:00 PM EDT
   NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug ...
   READ ARTICLE

9. Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

   GlobeNewswire APR 2, 2025 7:00 AM EDT
   The undisclosed target is a central regulator of inflammation that is distinct from the previousl...
   READ ARTICLE

10. Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

    GlobeNewswire MAR 25, 2025 4:30 PM EDT
    SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clin...
    READ ARTICLE